Dexcom, glowing from fabulous results, dismisses Medtronic as a viable CGM competitor at JPM
Dexcom's executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
Dexcom's executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest - and investment - in the space.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Medtronic said the company will be rolled into its Diabetes Group to improve its diabetes management capabilities by adding Nutrino's comprehensive food database, food analysis system and nutrition-science expertise.
An expensive failed acquisition, sales force flux, off-label use of a controversial biologics product, a DOJ investigation and nimble competitors chipping away has hobbled Medtronic's spine business. The purchase of Mazor Robotics aims to be a major reset.
In less than a decade, the chief patient officer - and similar roles with different titles - has become a key part of the healthcare industry executive team.
Medtronic had previously betted on higher adoption of its insulin pumps tethering the use of continuous glucose monitors to those pumps but has recently returned to the standalone CGM market with the launch of its Guardian Connect device in the U.S. Should Dexcom and Abbott worry?
In a bid to expand into the larger, more lucrative type 2 diabetes market, the medical device maker offers a performance guarantee to payers and employers tied to its MiniMed 670G insulin pump system.
With the FDA approval of a new continuous glucose monitoring system with machine learning capabilities to predict highs and lows in blood-glucose levels, Medtronic makes a bigger play for type 2 diabetes patients.
After a Type 1 patient penned a post on why she didn't think Medtronic's 670G hailed as the first artificial pancreas was all that, another patient who uses the device writes it's exactly that and then some.
As a type 1 diabetes patient, I have decided to stay on an open-source insulin delivery solution instead of switching to a hybrid closed-loop insulin delivery system from Medtronic whose FDA approval was widely hailed.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Omar Ishrak highlights a few products with which Medtronic hopes to succeed in value-based care and responds to criticism about how it approaches high-growth companies from an acquisitions.
Fitbit CEO and chairman James Park outlined the company's progress in a conference call late Wednesday to discuss the company's earnings in the third quarter.
Telemedicine and EHR vendors figured into deals involving Medtronic, CVS and Zocdoc, among other businesses.
Medtronic and SPR Therapeutics are treating chronic pain but while the former has adopted a permanent, implantable neuromodulation treatment, the latter is going the temporary wearable route.
The paternalistic worldview of the "doctor knows best" is (largely) on the way out. But what if it's replaced by data? Could data one day silence the intangible reasons patients have for requesting different therapies; or be used to deny certain therapies based on a set of probabilities?